Analytical, Diagnostic and Therapeutic Techniques and Equipment
Administration, Metronomic
TemozolomideChemotherapy regimensOutcomesAntiangiogenicAdministration of chemotherapeuticClinicallyChemotherapeutic agentsClinicalRecurrentSystemicToxicityCancer TherapyImmuneAnticancerEfficacyRecurrenceAggressiveGeneTreatmentCharacteristicsStudySurvivalCurrentUnresectableRadiation therapyPatientsCombinationCellsResultsImprove
Temozolomide2
  • The first Phase 1b clinical trial of zotiraciclib in GBM, sponsored by the National Cancer Institute (NCI), is a multi-arm, dose-finding study examining zotiraciclib plus dose-dense or metronomic temozolomide (TMZ) in adults with recurrent anaplastic astrocytoma and GBM. (wikipedia.org)
  • In his study, Clinical endpoint, Capecitabine, Metronomic Chemotherapy and Temozolomide is strongly linked to Phases of clinical research, which falls under the umbrella field of Colorectal cancer. (research.com)
Chemotherapy regimens2
  • The results alert to a potential risk in current empirically based continuous low-dose chemotherapy regimens such as metronomic chemotherapy. (researchsquare.com)
  • Despite the recent development of new chemotherapy regimens and the introduction of biological therapies, the 5-year survival for advanced GC is still very low, and the median overall survival remains less than 1 year[ 5 ]. (biomedcentral.com)
Outcomes3
  • Key to optimizing patient outcomes is an understanding of the evolution and current role of these therapies in the HCC landscape. (bvsalud.org)
  • As a result of these activities, TSPs can also control drug delivery and activity, tumor response and resistance to therapies, with different outcomes depending on the nature of TSP-interacting cell types, receptors, and ligands, in a highly context-dependent manner. (bvsalud.org)
  • Secondary outcomes will include safety and toxicity of each therapy administered. (biomedcentral.com)
Antiangiogenic3
  • This review, focusing primarily on TSP-1, discusses the effects of TSPs on tumor response to chemotherapy, antiangiogenic, low-dose metronomic chemotherapy, immunotherapy, and radiotherapy, by analyzing TSP activity on different cell compartments - tumor cells, vascular endothelial cells and immune cells. (bvsalud.org)
  • These findings indicate that the combination of Ad-mediated antiangiogenic gene therapy and oncolytic Ad therapeutics could be one of promising comprehensive treatment strategies for GC. (biomedcentral.com)
  • Antiangiogenic gene therapy can overcome these problems and represents a promising new approach for the treatment of cancer. (biomedcentral.com)
Administration of chemotherapeutic1
  • For tumors resistant to radiation and for those animals unable to receive radiation therapy, systemic treatment with administration of chemotherapeutic agents, including melphalan, chlorambucil, cyclophosphamide, and glucocorticoids, have been recommended and have yielded long-term survival. (merckvetmanual.com)
Clinically2
  • Investigation of clinically tested therapies for children with recurrent MB has significant implications for clinical practice. (biomedcentral.com)
  • The current metronomic chemotherapy protocols applied clinically are exclusively empirical in terms of dosing (e.g., half, one third, one tenth of the maximum tolerated dose) and scheduling (e.g., weekly, twice a week, thrice a week, daily) due to the lack of theory-based dose setting method. (researchsquare.com)
Chemotherapeutic agents1
  • Therapies tested include traditional medical chemotherapeutic agents and new generation targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors, hormone blocking therapies, and an array of over forty nutrient, biological and herbal therapies. (dunphynunley.com)
Clinical9
  • Numerous clinical trials are currently investigating the role of different immune modulators either as monotherapy or as combination therapy in the neoadjuvant setting. (bvsalud.org)
  • We analyzed clinical data to evaluate the frequency of intracranial progression in advanced NSCLC patients treated with PD-1 blockade therapies compared with those treated without PD-1 blockade therapies, and found that the frequency of intracranial progression in advanced NSCLC patients treated with PD-1 blockade therapies was significantly lower than that in patients treated with cytotoxic chemotherapies. (bvsalud.org)
  • Advances in medicine emerge from prospective clinical trials, which allow patients with a given disease and meeting specific eligibility criteria to access studies that provide a controlled assessment of a therapy. (abta.org)
  • Despite best current therapies, patients with recurrent MB experience have an alarmingly high mortality rate and often have limited therapeutic options beyond inadequate chemotherapy or experimental clinical trials. (biomedcentral.com)
  • Therefore, a systematic review of the literature regarding treatment strategies employed in recurrent pediatric MB will evaluate previous salvage therapies in order to guide future clinical trials. (biomedcentral.com)
  • By reviewing the efficacy and toxicity of MB salvage therapies, this study will identify effective therapeutic strategies administered to recurrent MB patients and can inform future clinical trials aimed to improve patient survivorship and quality of life. (biomedcentral.com)
  • As a result, the clinical development of metronomic chemotherapy has been impeded by numerous limitations, including the lack of its basic pharmacological data, ambiguity of its definition and the resulting empiric design of treatment protocols. (researchsquare.com)
  • Clinical and histopathological characteristics were re-examined. (rare-cancer.org)
  • Gene therapy using a recombinant adenovirus (Ad) encoding secretory human endostatin (Ad-Endo) has been demonstrated to be a promising antiangiogenesis and antitumor strategy of in animal models and clinical trials. (biomedcentral.com)
Recurrent3
  • The aim of this systematic review will be to investigate the efficacy and safety of salvage therapies for the management of children with progressive, treatment-refractory, or recurrent MB. (biomedcentral.com)
  • In additional analyses, we will investigate the role of re-irradiation and mono- vs. poly-therapy in recurrent disease, and whether molecular subgrouping of MB influences salvage therapy. (biomedcentral.com)
  • Consequently systemic therapy continues to be the most often utilized treatment in recurrent HGG. (surgicalneurologyint.com)
Systemic1
  • In mice, this three-step therapy induced CD4- and CD8-dependent systemic immune responses that enhanced T-cell infiltration into distant tumors, leading to their eradication and significantly improving survival. (aacrjournals.org)
Toxicity1
  • Studies examining the survival and toxicity of therapies administered to treatment-refractory pediatric MB patients will be included. (biomedcentral.com)
Cancer Therapy1
Immune2
  • Given successes in the setting of unresectable hepatocellular carcinoma (HCC) and the advantages of neoadjuvant therapy, many trials are demonstrating the safety and feasibility of combination of immune checkpoint inhibitors (ICIs)/tyrosine kinases in patients with resectable HCC. (bvsalud.org)
  • The plethora of molecularly targeted therapies and immune checkpoint inhibitors under investigation represent the new horizon of treatment of HCC not only in advanced stages but also potentially at every stage of diagnosis and management. (bvsalud.org)
Anticancer2
  • Finally, we examine possible approaches to develop TSP-based compounds as therapeutic tools to potentiate the efficacy of anticancer therapy. (bvsalud.org)
  • Regarding this specific, cyclophosphamide at a single lower serving exhibited an exceptional anticancer report compared to same substance provided with a metronomic plan. (pdgfrsignals.com)
Efficacy2
  • Furthermore, evaluating the available therapies in more homogeneous population might improve their efficacy through a perfect tailoring of treatment options. (springeropen.com)
  • Blood Results of the only phase , multicenter, open label study evaluated the efficacy and safety of tipifarnib compared with best supportive care, including hydroxyurea, as first line therapy in elderly patients with newly diagnosed, de novo, or secondary acute myeloid leukemia. (alk-inhibitors.com)
Recurrence1
  • If intracranial recurrence occurs during the treatment with PD-1 blockade therapies, aggressive local therapies could be worthwhile. (bvsalud.org)
Aggressive2
  • It is important to block the activity of multiple genes to successfully regulate cancer expression because single therapies are extremely rare in cancer care, as they often allow the cancer genome to adapt and become more aggressive. (dunphynunley.com)
  • If a patient is treated with a wrong or inadequate therapy, the cancer will grow more aggressive in time. (dunphynunley.com)
Gene3
  • All of us previously noted a potent antitumor aftereffect of an individual low-dose cyclophosphamide as well as interleukin-12 (IL-12) gene therapy in opposition to sophisticated gastrointestinal carcinoma, inside rats. (pdgfrsignals.com)
  • Right here, all of us assessed perhaps the shipping involving IL-12 by gene treatment in addition to metronomic cyclophosphamide exerts antitumor effects in a murine style of intestines carcinoma. (pdgfrsignals.com)
  • Nonetheless, metronomic cyclophosphamide plus IL-12 gene treatment still did not increase the number of tumor-infiltrating To lymphocytes as well as, moreover, to be able to cause a certain antitumor defense reaction. (pdgfrsignals.com)
Treatment2
  • When tumors are multiple or when surgical excision is not feasible, radiation therapy appears to be the best secondary treatment. (merckvetmanual.com)
  • Also available now are three other treatments that have FDA approval for tumors that have recurred or have progressed after initial treatment: Avastin, Gliadel, and an electrical field therapy named Novocure TTF. (gotomydoctor.com)
Characteristics1
  • Importantly, the presences of distinctive CSC populations that are endowed with differential functional characteristics suggest that a combination of targeted therapies will be necessary for successful cure of HCC. (molcells.org)
Study2
  • The various areas that Giuseppe Tonini examines in his Cancer study include Prospective cohort study, Pathology, Immunology and Genotype. (research.com)
  • Seven black pacu averaging approximately 13 kg were examined in this study. (vin.com)
Survival1
  • Although applying multi-modal therapies (radiation, chemotherapy, and surgery) has increased 5-year survival amongst standard-risk MB patients, overall survival (OS) rates seem to have plateaued. (biomedcentral.com)
Current1
  • This systematic review will provide an overview of the current literature regarding salvage therapies for relapsed MB patients. (biomedcentral.com)
Unresectable1
  • With advances in locoregional therapy for unresectable HCC during the last 2 decades and the recent expansion of transplant criteria for HCC, as well as ongoing organ shortages, patients are spending more time on the waitlist, which has resulted in an increased usage of locoregional therapies. (bvsalud.org)
Radiation therapy1
  • And then radiation therapy is a whole different ball of wax where it's always gonna be thousands, and it's a, it's a tough number. (dogcancer.com)
Patients1
  • Occassional patients may be candidates for re-irradiation but again there is a paucity of data to commend this therapy and only a minority of selected patients are eligible for this approach. (surgicalneurologyint.com)
Combination1
  • The results not only help the practitioner and patient choose an effective combination of therapies, but also helps them understand which cancer genes (oncogenes) are blocked by which treatments. (dunphynunley.com)
Cells3
  • At present, a European lab offers a blood test which filters and isolates circulating tumor cells (a.k.a. micrometastatic cells) from a patient's blood, genetically fingerprints them, then pharmacogenetically tests the cells for the effectiveness of various medical therapies. (dunphynunley.com)
  • This mixture therapy had been able, no less than to some extent, in order to opposite immunosuppression, by simply lowering the number of regulatory Capital t cellular material (Tregs) and also of splenic myeloid-derived suppressor cells (MDSCs). (pdgfrsignals.com)
  • Formerly, studies have only ever examined cells in a lab, then looked into the effect of alcohol on those cells. (veritalife.com)
Results1
  • The results showed that tumor formation and growth were both significantly promoted by GEM or GEM+CDDP at as low as half of the metronomic dosages, which were accompanied by enhancements of angiogenesis in tumor tissues and the release of proangiogenic BMDCs in the circulating blood. (researchsquare.com)
Improve1